Price Alert

Corcept Therapeutics (CORT)

NASDAQ: CORT · Real-Time Price · USD

79.47

2.66 (3.46%)

At close: Oct 16, 2025, 3:59 PM

79.70

0.29%

After-hours: Oct 16, 2025, 07:45 PM EDT

3.46% (1D)

Bid	76
Market Cap	8.37B
Revenue (ttm)	716.08M
Net Income (ttm)	132.52M
EPS (ttm)	1.12
PE Ratio (ttm)	70.96
Forward PE	36.61
Analyst	Buy
Dividends	n/a

Ask	85
Volume	1,182,492
Avg. Volume (20D)	865,309
Open	78.11
Previous Close	76.81
Day's Range	76.34 - 79.58
52-Week Range	42.01 - 117.33
Beta	0.46
Ex-Dividend Date	n/a

About CORT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CORT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CORT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Corcept Therapeutics is scheduled to release its earnings on Oct 29, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

+6.5%

Corcept Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

4 months ago

-7.58%

Corcept Therapeutics shares are trading lower. The company reported its Phase 3 ROSELLA trial results.

News

1 day ago · zacks.com

CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer

Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.

1 day ago · seekingalpha.com

Corcept Transition To New Specialty Pharmacy Well Underway

Corcept Therapeutics (CORT) has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing CORT prescriptions due to it...

2 days ago · businesswire.com

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...

2 weeks ago · zacks.com

Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?

Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.

2 weeks ago · businesswire.com

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics

ATLANTA--(BUSINESS WIRE)--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to ther...

2 weeks ago · seekingalpha.com

Corcept Primed For An Upside EPS Surprise

My September quarter EPS forecast of $0.29 for Corcept could meaningfully beat analyst projections of $0.17. Approval of the company's Relacorilant medication by the FDA will essentially resolve any g...